VIRACHEM市场信息门户
B2B 平台
实时 · Q4 2026·贸易网络 活跃品种: 24·FX ECB · — —:— CET·更新频率 每小时portal v3 · —
行情价格新闻博客方法论B2B 平台
Live · Q4 2026

欧盟市场，
尽在一处。

ViraChem B2B 平台背后的信息层。实时现货价格、来自公开注册库的 R&D 新闻，以及面向全欧洲制药与生物技术实验室的实地研究——直接源自我们的贸易网络，每小时更新。

浏览实时价格 →打开 R&D 新闻源
已定价条目
24
原料粉末 · 千克档价
7 日均值 Δ
+0.8%▲
涵盖活跃品种
FX · ECB
EUR/USD
每日参考汇率
更新频率
1 h
每行现货的 TTL
/ 02 现货价格

实时价格与分析/ 7-day spot · €/g · 24 compounds

每小时更新全部化合物 →
BPC-157 acetate · In Vivo
BPC · CAS 137525-51-0 · MW 1419.5
7d
€/g
€156/g▼~-5.5%
−30d−20d−10d当前
区间
€156.77
HPLC 纯度
≥98%
Grade
In Vivo
GHK-cu acetate · In Vivo
GHK · CAS 89030-95-5 · MW 401.91
7d
€/g
€4/g▼~-3.5%
−30d−20d−10d当前
区间
€4.39
HPLC 纯度
≥98%
Grade
In Vivo
Mots-c acetate · In Vivo
MOT · CAS 1627580-64-6 · MW 2174.6
7d
€/g
€277/g▼~-4.8%
−30d−20d−10d当前
区间
€274.36
HPLC 纯度
≥98%
Grade
In Vivo
CJC 1295 NO DAC acetate · In Vivo
CJC · CAS 863288-34-0 · MW 3367.9
7d
€/g
€512/g▼~-1.4%
−30d−20d−10d当前
区间
€509.52
HPLC 纯度
≥98%
Grade
In Vivo
化合物 · 化学信息
7 日走势
€/g · 现货
1d · 7d · 30d
HPLC 纯度
BPC-157 acetate structure
BPCBPC-157 acetate· raw powder
In Vivoacetate
CAS137525-51-0MW1419.5 g/mol盐型acetateCID9941957SEQGEPPPGKPADDAGLVInChIHEEWEZGQMLZMFE-RKGINYAYSA-N
€156/g
1d~+2.6%7d▼ ~-5.5%30d~+11.1%
≥98%
→
GHK-cu acetate structure
GHKGHK-cu acetate· raw powder
In Vivoacetate
CAS89030-95-5MW401.91 g/mol盐型acetateCID139035031SEQGly-His-Lys (Cu²⁺)InChILREZPQNYQZAPJC-ACMTZBLWSA-L
€4/g
1d~-0.7%7d▼ ~-3.5%30d~-11.2%
≥98%
→
Mots-c acetate structure
MOTMots-c acetate· raw powder
In Vivoacetate
CAS1627580-64-6MW2174.6 g/mol盐型acetateCID146675088SEQMRWQEMGYIFYPRKLRInChIWYTHCOXVWRKRAH-LOKRTKBUSA-N
€277/g
1d~-1.3%7d▼ ~-4.8%30d~-2.8%
≥98%
→
CJC 1295 NO DAC acetate structure
CJCCJC 1295 NO DAC acetate· raw powder
In Vivoacetate
CAS863288-34-0MW3367.9 g/mol盐型acetateCID56841945SEQY-(D-A)-D-A-I-F-T-Q-S-Y-R-K-V-L-A-Q-L-S-A-R-K-L-L-Q-D-I-L-S-R-NH2InChIXOZMWINMZMMOBR-HRDSVTNWSA-N
€512/g
1d~+1.6%7d▼ ~-1.4%30d~+14.2%
≥98%
→
Epithalon acetate structure
EPIEpithalon acetate· raw powder
Industrialacetate
CAS64082-79-7MW390.35 g/mol盐型acetateCID219042SEQAEDGInChIHGHOBRRUMWJWCU-FXQIFTODSA-N
€105/g
1d~+0.5%7d▲ ~+9.3%30d~+3.2%
>90%
→
Thymosin alpha 1 acetate structure
THYThymosin alpha 1 acetate· raw powder
In Vivoacetate
CAS62304-98-7MW3108.3 g/mol盐型acetateCID16130571SEQSDAAVDTSSEITTKDLKEKKEVVEEAENInChINZVYCXVTEHPMHE-ZSUJOUNUSA-N
€562/g
1d~-2.2%7d▼ ~-5.7%30d~-4.6%
≥98%
→
Thymulin acetate structure
THY3Thymulin acetate· raw powder
Industrialacetate
CAS63958-90-7MW858.9 g/mol盐型acetateCID71300623SEQXAKSQGGSNInChILIFNDDBLJFPEAN-YTAPOSPOSA-N
€165/g
1d~-0.2%7d▼ ~-4.5%30d~-6.0%
>90%
→
5-Amino 1MQ chloride structure
AMI5-Amino 1MQ chloride· raw powder
In Vivochloride
CAS685079-15-6MW159.21 g/mol盐型chlorideCID950107InChIZMJBCEIHNOWCMC-UHFFFAOYSA-O
€2/g
1d~+3.3%7d▼ ~-2.4%30d~-9.1%
≥98%
→
AOD-9604 acetate structure
AODAOD-9604 acetate· raw powder
In Vivoacetate
CAS221231-10-3MW1815.1 g/mol盐型acetateCID71300630SEQYLRIVQCRSVEGSCGFInChIGVIYUKXRXPXMQM-BPXGDYAESA-N
€874/g
1d~-1.6%7d▼ ~-5.4%30d~-9.8%
≥98%
→
DSIP acetate structure
DSIDSIP acetate· raw powder
In Vivoacetate
CAS62568-57-4MW848.8 g/mol盐型acetateCID68816SEQWAGGDASGEInChIZRZROXNBKJAOKB-GFVHOAGBSA-N
€196/g
1d~+3.7%7d▲ ~+7.9%30d~+10.4%
≥98%
→
Ipamorelin acetate structure
IPAIpamorelin acetate· raw powder
In Vivoacetate
CAS170851-70-4MW711.9 g/mol盐型acetateCID9831659SEQXHXFKInChINEHWBYHLYZGBNO-BVEPWEIPSA-N
€243/g
1d~-0.9%7d▼ ~-4.8%30d~+5.3%
≥98%
→
KPV
KPVKPV acetate· raw powder
In Vivo
€223/g
1d~+0.1%7d▼ ~-1.7%30d~-7.5%
≥98%
→
Kisspeptin-10 acetate structure
KISKisspeptin-10 acetate· raw powder
In Vivoacetate
CAS374675-21-5MW1302.4 g/mol盐型acetateCID25240297SEQYNWNSFGLRFInChIRITKWYDZSSQNJI-INXYWQKQSA-N
€285/g
1d~-3.1%7d▼ ~-5.3%30d~-4.3%
≥98%
→
LL-37 acetate structure
LLALL-37 acetate· raw powder
In Vivoacetate
CAS154947-66-7MW4493 g/mol盐型acetateCID16198951SEQLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESInChIPOIUWJQBRNEFGX-XAMSXPGMSA-N
€774/g
1d~+2.8%7d▲ ~+3.7%30d~+0.3%
≥98%
→
Melanotan 2 acetate structure
MELMelanotan 2 acetate· raw powder
Industrialacetate
CAS121062-08-6MW1024.18 g/mol盐型acetateCID92432SEQXDHFRWKInChIJDKLPDJLXHXHNV-MFVUMRCOSA-N
€162/g
1d~-3.7%7d▲ ~+5.7%30d~+12.6%
>90%
→
NAD+ structure
NADNAD+· raw powder
In Vivo
CAS53-84-9MW663.4 g/molCID5892InChIBAWFJGJZGIEFAR-NNYOXOHSSA-N
€1/g
1d~+4.7%7d▲ ~+8.5%30d~+8.5%
≥98%
→
PEG
PEGPEG-MGF acetate· raw powder
In Vivoacetate
MW4888 g/mol盐型acetateSEQYQPPSTNKNTKSQRRKGSTFEERK-NH2
€1,380/g
1d~+1.4%7d▲ ~+11.0%30d~+14.9%
≥98%
→
PT-141 acetate structure
PTAPT-141 acetate· raw powder
In Vivoacetate
CAS189691-06-3MW1025.2 g/mol盐型acetateCID9941379SEQXDHFRWKInChIFFHBJDQSGDNCIV-MFVUMRCOSA-N
€378/g
1d~0.0%7d▲ ~+6.3%30d~+0.4%
≥98%
→
Retatrutide acetate structure
RETRetatrutide acetate· raw powder
In Vivoacetate
CAS2381089-83-2MW4731.33 g/mol盐型acetateCID171390338SEQY-Aib-QGTFTSDYSI-αMeLeu-LDK-Lys(19-carboxy-nonadecanoyl-γGlu-AEEA)-AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH₂InChIMLOLQJNKXBNWFW-SAGGEDDASA-N
€164/g
1d~-3.6%7d▼ ~-8.2%30d~-12.4%
≥98%
→
SS-31 acetate structure
SS3SS-31 acetate· raw powder
In Vivoacetate
CAS736992-21-5MW639.8 g/mol盐型acetateCID11764719SEQRXKFInChISFVLTCAESLKEHH-WKAQUBQDSA-N
€329/g
1d~+2.6%7d▲ ~+11.0%30d~+2.0%
≥98%
→
Selank acetate structure
SELSelank acetate· raw powder
In Vivoacetate
CAS129954-34-3MW751.9 g/mol盐型acetateCID11765600SEQTKPRPGPInChIJTDTXGMXNXBGBZ-YVHUGQOKSA-N
€187/g
1d~+1.7%7d▼ ~-0.9%30d~-9.1%
≥98%
→
Semax acetate structure
SEMSemax acetate· raw powder
In Vivoacetate
CAS80714-61-0MW813.9 g/mol盐型acetateCID9811102SEQMEHFPGPInChIAFEHBIGDWIGTEH-AQRCPPRCSA-N
€192/g
1d~+1.4%7d▲ ~+2.9%30d~+9.5%
≥98%
→
Tesamorelin acetate structure
TESTesamorelin acetate· raw powder
In Vivoacetate
CAS218949-48-5MW5136 g/mol盐型acetateCID16137828SEQYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARLInChIQBEPNUQJQWDYKU-BMGKTWPMSA-N
€541/g
1d~+1.4%7d▲ ~+5.8%30d~+3.0%
≥98%
→
Thymosin beta-4 acetate structure
THY4Thymosin beta-4 acetate· raw powder
In Vivoacetate
CAS77591-33-4MW4963 g/mol盐型acetateCID45382195SEQSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGESInChIUGPMCIBIHRSCBV-UHFFFAOYSA-N
€571/g
1d~+0.6%7d▲ ~+2.3%30d~-2.1%
≥98%
→

Prices derive from ViraChem’s active network of trade, converted to EUR at the ECB daily reference rate for each transaction date. 方法论 →

24 compounds·€/g·ECB · EUR/USD 1.1188·Updated 07:59 CET·Q4 2026
/ 03 新闻脉动

新闻脉搏与最新研究/ 公开注册库 · 博客

每小时更新完整新闻源 →
R&D 新闻源EUROPE PMC · CT.GOV
13 OCT
预印本bioRxiv· immunology
Self-reactive human CD8⁺ T cells restricted by HLA-E mediate immunoregulatory and antiviral functions
HLA-E constitutively presents self VL9 peptides on healthy cells, signaling an intact HLA class I pathway and protecting cells from natural killer cell attack. Beyond this canonical role, HLA-E-restricted CD8 T cells …
Walters, L. C.; Guo, X.; Casquero, C.; Urbach, J. M.; Leddy, O.; Cakan, E.; Chan, A. O.; Balivada, P. A.; Wisner, H.; Bryson, B. D.; Whit…
↗
13 OCT
临床试验ClinicalTrials.gov· PHASE3 · RECRUITING
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer …
Merck Sharp & Dohme LLC
↗
13 OCT
临床试验ClinicalTrials.gov· PHASE2 · NOT_YET_RECRUITING
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
This trial proposes to evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal in…
Kalinski, Pawel, MD, PhD
↗
13 OCT
临床试验ClinicalTrials.gov· PHASE2 · RECRUITING
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the…
National Cancer Institute (NCI)
↗
13 OCT
临床试验ClinicalTrials.gov· PHASE2 · RECRUITING
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chem…
Medical University of Vienna
↗
13 OCT
临床试验ClinicalTrials.gov· PHASE2 · NOT_YET_RECRUITING
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer
Bristol-Myers Squibb
↗
最新研究实地札记 · 分析
Analytical Science
Novo Nordisk Study Finds Follow-On Liraglutide Less Physically Stable Than Originator
ViraChem Research Desk05 Aug6 分钟阅读
Clinical Research
Genetic Analysis Argues for Lower GIP While Tirzepatide Agonises the Receptor
ViraChem Research Desk05 Aug8 分钟阅读
Regulatory
Consensus Statements Fill the GLP-1 Evidence Gap Regulators Have Not
ViraChem Research Desk02 Aug8 分钟阅读
Clinical Research
Low-Dose Tirzepatide Matched 5 mg on Weight Loss in a 112-Patient Japanese Cohort
ViraChem Research Desk02 Aug8 分钟阅读
Clinical Research
Semaglutide Withdrawal Trial Asks Whether Tapering Beats Stopping Cold
ViraChem Research Desk31 Jul8 分钟阅读
24 compounds·€/g·ECB · EUR/USD 1.1188·Updated 07:59 CET·Q4 2026
/ 04 方法论

数据是如何构建的/ 来源 · 换算 · 刷新

完整方法论 →
M · 01

真实交易数据

每一个现货价格都来自流经 ViraChem 欧盟贸易网络的真实订单——不是问卷调查，也不是抓取的目录价。

数据来源 →M · 02

按 ECB 汇率折算的 EUR

非欧元交易按各交易日的欧洲央行每日参考汇率折算为欧元。所有现货价格采用同一套换算惯例。

折算方式 →M · 03

每小时刷新

现货价格、趋势变动与行情行每小时刷新一次。每一行都带有 TTL，因此下游系统可以审计数据的新鲜度。

更新频率 →
24 compounds·€/g·ECB · EUR/USD 1.1188·Updated 07:59 CET·Q4 2026
/ 05 探索

研究分类/ 3 working lenses

浏览归档 →
CAT · 01

Analytical Science

Characterisation, impurity profiling, and stability of peptide materials.

1
文章
→
CAT · 02

Clinical Research

Trial design, results, and pipeline movement in peptide therapeutics.

5
文章
→
CAT · 03

Regulatory

EMA, FDA and pharmacopoeial developments affecting peptide drug substance and product.

1
文章
→
/ 06 数据来源
Europe PMCClinicalTrials.govUSPTObioRxivECB
公开注册库 · 每日更新
/ 交易平台

想要采购，
而不只是阅读？

B2B 网络平台——产品目录、询价（RFQ）工具、分析文档与欧盟配送——位于 virachemical.com。

访问 virachemical.com
/ 我们的业务

成品规格、定制生产、灌装与包装。

涵盖 11 个类别的 71 项等级规格——Pharma、Cosmetic、Food、Analytical、IVD、Cell culture、Industrial 等。

浏览服务
/ 获取报价

询价与阶梯量报价，1 个工作日内回复。

告诉我们化合物、规模与形式。我们会回复可供情况、交期与欧盟到岸成本。

索取报价